Physician profile
Aaron Harmon
NPI 1932822053
$4,736.74
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $212 · 2023: $1,923 · 2024: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,471 · Education: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,470.96 |
| Education | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.47 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $684.00 | 2022-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $588.98 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.05 | 2022-2024 | Caplyta |
| Corium, LLC | $365.26 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $342.32 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $219.90 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $180.03 | 2024 | Fanapt, Hetlioz |
| Alkermes, INC. | $171.22 | 2023-2024 | Lybalvi, Aristada |
| Tris Pharma INC | $167.05 | 2023-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $148.07 | 2023-2024 | Uzedy, Austedo Xr |
| Lundbeck LLC | $121.55 | 2023-2024 | Rexulti |
| Menarini Silicon Biosystems, INC. | $92.23 | 2023 | Cellsearch |
| Noven Therapeutics, LLC | $84.03 | 2023 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $61.06 | 2024 | Relexxii, Methylphenidate Hydrochloride |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $32.30 | 2023 | Daybue |
| E.R. Squibb & Sons, L.L.C. | $17.58 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.